Cyramza 10 mg/ml IV Infusion Uses, Dosage, Side Effects and more

Cyramza 10 mg/ml IV Infusion is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Cyramza 10 mg/ml IV Infusion is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.

Attribute	Details
Trade Name	Cyramza 10 mg/ml IV Infusion
Availability	Prescription only
Generic	Ramucirumab
Ramucirumab Other Names	Ramucirumab
Related Drugs	Opdivo, methotrexate, Keytruda, capecitabine, pembrolizumab, fluorouracil, doxorubicin, cisplatin, Tagrisso, Avastin
Weight	10 mg/ml
Type	IV Infusion
Formula	C₆₃₇₄H₉₈₆₄N₁₆₉₂O₁₉₉₆S₄₆
Weight	143600.0 Da
Groups	Approved, Investigational
Therapeutic Class
Manufacturer	Healthcare Pharmaceuticals Ltd.
Available Country	Bangladesh
Last Updated:	January 7, 2025 at 1:49 am

Uses

Cyramza 10 mg/ml IV Infusion is an antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.

For use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.

Cyramza 10 mg/ml IV Infusion is also used to associated treatment for these conditions: Advanced Gastric Cancer, Advanced gastro-esophageal junction adenocarcinoma, Refractory, metastatic Colorectal cancer, Refractory, metastatic Non small cell lung cancer

How Cyramza 10 mg/ml IV Infusion works

See simplified version Cyramza 10 mg/ml IV Infusion also Cyramza 10 mg/ml IV Infusion in bangla

Toxicity

Cyramza 10 mg/ml IV Infusion packaging includes warnings for arterial thromboembolic events, hypertension, infusion-related reactions, gastrointestinal perforation, clinical deterioration in patients with cirrhosis, and reversible posterior leukoencephalopathy syndrome. The most common reactions observed in single-agent-treated patients at a rate of >10% and >2% higher than placebo were hypertension and diarrhea. The most common adverse reactions observed in patients treated with ramucirumab plus paclitaxel at a rate of of >30% and >2% higher than placebo plus paclitaxel were fatigue, neutropenia, diarrhea, and epistaxis.